Chronic pancreatitis

DiMagno, Matthew; DiMagno, Eugene P.

doi:10.1097/01.mog.0000239862.96833.89

Cited by 16 publications

(11 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is, however, considerable concern of the overall accuracy of FE-1 in diagnosing PEI, as it is known that it correlates poorly to CFA [35,36,37]. The present study is therefore of particular importance as we found no statistical association between the CFA and the FE-1 test even with generous statistical manipulations to deal with potentially confounding factors.…”

Section: Discussioncontrasting

confidence: 50%

Partial Pancreatic Resection for Pancreatic Malignancy Is Associated with Sustained Pancreatic Exocrine Failure and Reduced Quality of Life: A Prospective Study

et al. 2011

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 50%

Partial Pancreatic Resection for Pancreatic Malignancy Is Associated with Sustained Pancreatic Exocrine Failure and Reduced Quality of Life: A Prospective Study

et al. 2011

View full text Add to dashboard Cite

“…Peri-tumoral pancreatitis is very commonly encountered in main duct IPMNs as a consequence of the local effects of the tumor, and it would be preferable to not to designate these as chronic pancreatitis, since chronic pancreatitis is a specific disease entity, defined by a constellation of findings at the clinical level. 192–194 It may be more appropriate to be descriptive about these chronic changes as atrophy, inflammation and others.…”

Section: Resultsmentioning

confidence: 99%

Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract

et al. 2016

View full text Add to dashboard Cite

Background There are no established guidelines for pathologic diagnosis/reporting of IPMNs. Design An international multidisciplinary group brought together by the Verona Pancreas Group in Italy-2013, was tasked to devise recommendations. Results 1) Crucial to rule out invasive carcinoma with extensive (if not complete) sampling. 2) Invasive component is to be documented in a full synoptic report including its size, type, grade, stage. 3) The term “minimally invasive” should be avoided; instead, invasion size with stage and substaging of T1 (1a, b, c; ≤0.5, >0.5–≤1, >1 cm), is to be documented. 4) Largest diameter of the invasion, not the distance from the nearest duct, is to be used. 5) A category of “indeterminate/(suspicious) for invasion” is acceptable for rare cases. 6) The term “malignant” IPMN should be avoided. 7) The highest grade of dysplasia in the non-invasive component is to be documented separately. 8) Lesion size is to be correlated with imaging findings in cysts with rupture. 9) The main duct diameter, and if possible, its involvement is to be documented; however, it is not required to provide main vs branch duct classification in the resected tumor. 10) Subtyping as gastric/intestinal/pancreatobiliary/oncocytic/mixed is of value. 11) Frozen section is to be performed highly selectively, with appreciation of its shortcomings. 12) These principles also apply to other similar tumoral intraepithelial neoplasms (mucinous cystic neoplasms, intra-ampullary, intra-biliary/cholecystic). Conclusion These recommendations will ensure proper communication of salient tumor characteristics to the management teams, accurate comparison of data between analyses, and development of more effective management algorithms.

show abstract

“…Demonstrating the cost-effectiveness of TPIAT will be essential for financial coverage of TPIAT, and for minimizing financial barriers to access. The main issues relate to the direct costs of the procedure, the health economic impact (total health costs plus economic impact) of the disease, and the cost savings of successful abrogation of CP by TPIAT (27). The high operating costs of an islet autotransplant facility are similar in Europe and the U.S.A. after allowing for cost-of-living differences and staffing costs, and a comprehensive analysis of TPIAT undertaken in the U.K. demonstrated the cost-effectiveness of this procedure (28).…”

Section: Patient Selection Indications and Timing Of Tpiatmentioning

confidence: 99%

Total Pancreatectomy With Islet Autotransplantation

Bellin¹,

Gelrud²,

Arreaza-Rubín³

et al. 2014

Pancreas

View full text Add to dashboard Cite

A workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) focused on research gaps and opportunities in total pancreatectomy with islet autotransplantation (TPIAT) for the management of chronic pancreatitis (CP). The session was held on July 23, 2014 and structured into five sessions: (1) patient selection, indications, and timing; (2) technical aspects of TPIAT; (3) improving success of islet autotransplantation; (4) improving outcomes after total pancreatectomy; and (5) registry considerations for TPIAT. The current state of knowledge was reviewed; knowledge gaps and research needs were specifically highlighted. Common themes included the need to identify which patients best benefit from and when to intervene with TPIAT, current limitations of the surgical procedure, diabetes remission and the potential for improvement, opportunities to better address pain remission, GI complications in this population, and unique features of children with CP considered for TPIAT. The need for a multicenter patient registry that specifically addresses the complexities of CP and total pancreatectomy outcomes as well as post-surgical diabetes outcomes was repeatedly emphasized.

show abstract

Chronic pancreatitis

Cited by 16 publications

References 133 publications

Partial Pancreatic Resection for Pancreatic Malignancy Is Associated with Sustained Pancreatic Exocrine Failure and Reduced Quality of Life: A Prospective Study

Partial Pancreatic Resection for Pancreatic Malignancy Is Associated with Sustained Pancreatic Exocrine Failure and Reduced Quality of Life: A Prospective Study

Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract

Total Pancreatectomy With Islet Autotransplantation

Contact Info

Product

Resources

About